You are here: Home: Audio Program Guide: BCU 2 | 2008 Audio: BCU 2 | 2008
 
  Go to interview with Stephen E Jones, MD
Go to interview with Sir Richard Peto, FRS
Go to interview with Kathy S Albain, MD
Go to Roundtable Discussion
Go to interview with Joyce O’Shaughnessy, MD
Go to interview Nancy U Lin, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Jones, MD Stephen E Jones, MD
Director, Breast Cancer Research
Charles A Sammons Cancer Center
Baylor University Medical Center
Dallas, Texas
Chair, US Oncology Breast Cancer Research
Medical Director, US Oncology Research
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Critical appraisal of the US Oncology adjuvant trial of docetaxel/cyclophosphamide (TC) versus AC
Track 2 Adjuvant TC versus AC: Efficacy according to HER2 status
Track 3 Adjuvant TC versus AC: Overall survival and long-term toxicities
Track 4 Clinical use of adjuvant anthracyclines
Track 5 Adjuvant TC versus AC: Analysis of the elderly population
Track 6 TOPO II gene amplification and sensitivity to anthracyclines

Track 7 Clinical use of adjuvant TC
Track 8 Phase II pilot trial of docetaxel/cyclophosphamide with trastuzumab in HER2-positive early breast cancer
Track 9 Clinical use of adjuvant trastuzumab monotherapy
Track 10 Quality control for assessment of hormone receptor and HER2 status
Track 11 Predictive value of the Oncotype DX™ assay for postmenopausal women with hormone receptor-positive, node-positive breast cancer
Track 12 Case discussion: Oncotype DX for a patient with a 1.8-cm, hormone receptor-positive, HER2-negative, node-negative colloid carcinoma of the breast
Track 13 Translating clinical trial results from the metastatic to the adjuvant setting
Track 14 Clinical use of the epothilone B analog ixabepilone plus capecitabine
Track 15 Clinical use of capecitabine
Track 16 Regulatory review of bevacizumab for breast cancer
     
Peto, MD Sir Richard Peto, FRS
University of Oxford
Oxford, United Kingdom
  
  Click here to download the entire interview  
Track 1 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Track 2 EBCTCG Overview: Impact of postmastectomy radiation therapy
Track 3 Influence of ER and PR status on efficacy of adjuvant tamoxifen in the EBCTCG Overview
Track 4 Time course of recurrence for ER-positive versus ER-negative breast cancer
Track 5 ATLAS (Adjuvant Tamoxifen, Longer Against Shorter) trial
Track 6 Estimates of recurrence risk after five years of adjuvant tamoxifen
Track 7 EBCTCG: Overview of the benefits of adjuvant chemotherapy

Track 8 EBCTCG: Influence of ER status on the efficacy of adjuvant chemotherapy
Track 9 Trends toward overall reduction in breast cancer mortality
Track 10 Commentary on randomized trials as prerequisites for adjuvant therapy guidelines
     
Albain, MD Kathy S Albain, MD
Professor of Medicine
Loyola University Stritch School of Medicine
Director, Breast Clinical Research and Thoracic Oncology Programs
Cardinal Bernardin Cancer Center
Maywood, Illinois
  
  Click here to download the entire interview  
Track 1 SWOG-8814: Tamoxifen versus CAF with concurrent or sequential tamoxifen in node-positive disease
Track 2 Prognostic value of the Oncotype DX assay in the tamoxifen-only arm of SWOG-8814
Track 3 Prognostic value of the Oncotype DX assay in the chemotherapy-based arms of SWOG-8814
Track 4 Clinical role of Oncotype DX for patients with hormone receptor-positive, node-positive breast cancer
Track 5 Potential for selecting specific chemotherapies based on a patient’s risk of recurrence
Track 6 Translational research utilizing tissue from prior clinical trials


     
  Roundtable Discussion:  
Hudis, MD Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York		  
Miller, MD Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Associate Professor of Medicine
Department of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana 		 
  Click here to download the entire discussion  
Track 1 Updated results of the EBCTCG Overview
Track 2 EBCTCG: Declining rates of mortality associated with breast cancer
Track 3 EBCTCG: Influence of ER status on the efficacy of adjuvant chemotherapy
Track 4 Retrospective analysis of SWOG-8814 tumor blocks using Oncotype DX
Track 5 Clinical indications for Oncotype DX in patients with early node-positive breast cancer
Track 6 Meta-analysis of adjuvant trials with high-dose chemotherapy

Track 7 Adjuvant TC versus AC: Updated results of the US Oncology clinical trial
Track 8 Role of adjuvant anthracyclines according to HER2 status
Track 9 Adjuvant chemotherapy selection for patients with node-positive breast cancer
Track 10 ECOG-E2100: VEGF genetic polymorphisms and clinical outcomes

Track 11 Cardiac safety of adjuvant bevacizumab with dose-dense ACarrow nab paclitaxel
Track 12 Lack of need for steroid premedication with nab paclitaxel
Track 13 Efficacy associated with nab paclitaxel compared to paclitaxel and docetaxel
Track 14 ECOG-E2104: A Phase II adjuvant trial of bevacizumab and dose-dense ACarrow paclitaxel in women with node-positive breast cancer
Track 15 ECOG-E5103: Adjuvant ACarrow paclitaxel with or without bevacizumab
Track 16 ATLAS trial: Five versus 10 years of adjuvant tamoxifen

Track 17 Continuation of adjuvant tamoxifen beyond five years in premenopausal women
Track 18 Continuation of an adjuvant aromatase inhibitor beyond five years in postmenopausal women
     
O Joyce O’Shaughnessy, MD
Co-Director, Breast Cancer Research Program
Baylor-Charles A Sammons Cancer Center
Texas Oncology, PA
US Oncology
Dallas, Texas
  
  Click here to download the entire interview  
Track 1 Results from the US Oncology adjuvant trial comparing TC to AC
Track 2 US Oncology trial comparing six cycles of TC versus TAC in HER2-negative early breast cancer
Track 3 Clinical use of adjuvant TC
Track 4 Clinical trial combining nab paclitaxel with cyclophosphamide
Track 5 Proposed CALGB Phase III trial evaluating bevacizumab with nab paclitaxel, paclitaxel or ixabepilone in the metastatic setting
Track 6 Quality of life with nab paclitaxel versus docetaxel

Track 7 Clinical use of steroid premedication with nab paclitaxel
Track 8 Clinical trials evaluating nab paclitaxel in the first-line setting for metastatic disease
Track 9 Selecting first-line therapy for patients with visceral metastases
Track 10 Secreted protein acidic and rich in cysteine (SPARC) and response to nab paclitaxel
Track 11 Clinical use of the Oncotype DX assay in node-positive breast cancer
Track 12 Phase II randomized trial of irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer
Track 13 Clinical trials evaluating cetuximab in breast cancer
Track 14 Adjuvant trial of AC followed by docetaxel with or without capecitabine
     
     
Lin, MD Nancy U Lin, MD
Instructor in Medicine
Harvard Medical School
Medical Oncologist, Dana-Farber Cancer Institute
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Neoadjuvant trial of TCH
Track 2 Prognosis and treatment for patients with HER2- positive, T1N0 tumors
Track 3 Clinical use of adjuvant trastuzumab monotherapy
Track 4 Risk of recurrence for patients with a small, node-negative, HER2-positive tumor
Track 5 CNS as a site of recurrence after treatment with trastuzumab
Track 6 Clinical implications of CNS metastases in women with HER2-positive disease

Track 7 Penetration of anticancer therapies into the CNS
Track 8 Lapatinib in patients with brain metastases
Track 9 Response of brain metastases to systemic therapy
Track 10 Brain metastases in patients with well-controlled systemic disease

Track 11 Neurocognitive function in patients treated with cranial radiation therapy
Track 12 Options for patients with disease that progresses after whole-brain irradiation
Track 13 Clinical use of lapatinib
Track 14 Management of recurrent disease after adjuvant trastuzumab
Track 15 Toxicities associated with lapatinib/capecitabine
Track 16 Management of HER2-negative metastatic disease

Track 17 XCaliBr trial: Capecitabine/bevacizumab as first-line therapy for metastatic disease
Track 18 BETH and ALTTO trials for patients with HER2-positive early breast cancer
Track 19 Cardiac safety of trastuzumab with bevacizumab

Track 20 Management of bevacizumab-associated hypertension
Track 21 Phase II trial of lapatinib in combination with trastuzumab in patients with metastatic disease